Episode notes
Connor Williams was shocked when the data came back for GH001. What could this mean for the future of treatment-resistant depression? Listen to his exclusive interview with Dr. Valcheva, the CEO of GH Research, to find out.
PODCAST TEAM
Producer: Devon Leaver
Editor: Dominique Guerra
Featuring: Dr. Velichka (Villy) Valcheva MD, CEO of GH Research moderated by Connor Williams, Senior Research Analyst at RTW Investments.
Don't forget to listen to part 1 of Connor’s discussion on treatment resistant depression and psychedelics with Stephanie Sirota, Managing Partner and Chief Business Officer at RTW Investments.
FOLLOW US
Love our podcast? Follow us on LinkedIn at
Keywords
life scienceshealthcare investingbiotechpsychedelics